ET-02, a PAI-1 inhibitor, is not proven to be more effective than Minoxidil for hair loss. Other treatments like finasteride, dutasteride, PP405, and AMP-303 are also discussed, focusing on cellular senescence and oxidative stress.
A user is experiencing androgenic alopecia and is considering using Vichy's aminexil for hair regrowth. They seek advice on its effectiveness and whether to combine it with microneedling.
The user is seeking an alternative solvent for pyrilutamide due to skin irritation from ethanol and propylene glycol. They experienced similar issues with topical minoxidil.
A user experienced significant swelling after a hair and beard transplant, possibly due to an allergic reaction or improper post-surgery care. Despite dissatisfaction with the clinic's handling of grafts and customer service, the user appreciates the clinic's skill in achieving natural hairline density.
Minoxidil may not be effective due to low sulfotransferase activity, and the user considers adding tretinoin to the regimen. They are unsure about the timing and combination with microneedling.
The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.
Dutasteride doses matter for hair loss treatment and are more effective than finasteride. RU58841 is suggested for better gains, but side effect profiles should be considered.
Spraying pyrilutamide on the crown area shows noticeable improvement compared to using a dropper. Applying directly to the vertex is challenging without wasting the product.
Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.
The conversation is about finding reputable clinics in Canada or near the US border that offer DUT mesotherapy for hair loss. The user is seeking recommendations and cost information for these treatments.
The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
The user has been using RU58841 for 6 months without noticeable results and is considering dropping it while continuing oral minoxidil, daily dutasteride, and topical minoxidil. Another user suggests visiting a dermatologist to check for other conditions.
The user has been using RU58841 for about 2 months without noticeable results or side effects and is unsure if this duration is sufficient to judge its effectiveness. Other users suggest continuing the treatment for at least 6 months and ensuring the product's authenticity.
Minoxidil is highly toxic to cats and dogs, even in small amounts. Users suggest switching to oral minoxidil or taking precautions to prevent pet exposure.
Latanoprost/bimatoprost's effectiveness in hair loss treatment is discussed, with its potential to convert vellus hairs to terminal hairs. It works differently from minoxidil and finasteride, and may be best for hairline application, but is not a replacement for them due to price and mechanism.
The conversation is about using RU58841 for hair loss, discussing the stability of the powder form and the need for a carrier solution like KB or PG + ethanol. The user is advised to mix RU58841 with stemoxydine and store it properly, while also considering safety precautions.
Pyrilutamide's 0.5% solution showed minimal improvement, while the 1% solution appears more promising but costly. The user is currently using finasteride and oral minoxidil and considering adding Pyrilutamide if effective and affordable.
Fluridil's effectiveness and safety in treating hair loss are discussed, with higher concentrations showing potential success. Comparisons are made to other treatments like RU58841, Pyri, CB-03-01, and topical spironalactone.
The user experienced initial success with topical minoxidil and dutasteride mesotherapy but is now losing more hair and unsure if it's due to shedding or ineffective treatment. They are considering whether to try a different approach.
A user experienced severe chest pains and shortness of breath after using RU58841 for hair loss and was advised by a doctor that blocking androgens can weaken the heart. They decided to continue with finasteride, minoxidil, and a hair transplant instead.
The post discusses speeding up verteporfin trials for hair loss treatment. The original poster, involved in the trials, requests help in crowdsourcing doctor emails to spread awareness and gather more support for the trials.
A 17-year-old with AGA is considering Revitacare Haircare Mesotherapy, which includes hyaluronic acid, amino acids, zinc, and B vitamins, injected into the scalp. One reply dismisses it as ineffective.
The user experienced significant hair loss after 9 months of using 0.5mg dutasteride and oral minoxidil, possibly due to alopecia areata. It is advised to consult a doctor for accurate diagnosis and treatment, as dutasteride and finasteride may not be effective.
Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.
The conversation discusses the appearance and testing of RU58841 powder for hair loss treatment. Users also mention side effects of RU58841 and suggest alternatives like dutasteride and minoxidil.
A user suspects vaping has contributed to their hair loss and plans to quit while using Minoxidil and finasteride. They are unsure if hair regrowth will be due to quitting vaping or the medications.